引用本文
  •    [点击复制]
  •    [点击复制]
PDF HTML全文阅读
本文已被:浏览 2984次   下载 960 本文二维码信息
码上扫一扫!
改良经括约肌间瘘管结扎术治疗括约肌间型及经括约肌型肛瘘的临床效果研究
吴闯,徐进,汪庆明,张海岩,黄烃,朱智敏
上海市宝山区中西医结合医院上海 201999
摘要:
目的 观察改良经括约肌瘘管结扎术(MLIFT)治疗括约肌间型肛瘘(ISAF)及经括约肌型肛瘘(TSAF)的疗效。方法:选取2016年1月1日—2020年12月31日上海市宝山区中西医结合医院肛肠科收治的190例TSAF和ISAF患者,随机分为治疗组(行MLIFT术)、对照组(行肛瘘切除术),术后常规清创、换药治疗;比较两组术后第1、3、7、14、21、30天的创面疼痛(VAS)、创面出血、肛门坠胀感、尿潴留及肛门控便能力(FISI)评分,比较两组治愈率及复发率情况,比较两组患者术前及术后1年的肛管静息压、肛管收缩压及肛管排便压的差异。结果:治疗组、对照组治愈率分别为87.37%、94.75%,差异无统计学意义(P>0.05);治疗组、对照组复发率分别为7.37%、2.11%,差异无统计学意义(P>0.05);术后第1、3、7天,治疗组VAS评分、创面出血和术后第14天创面出血评分均高于对照组(P<0.01);术后第1、7天,治疗组患者肛门坠胀评分和术后第1天尿潴留患者明显低于对照组(P<0.01);术后1年,治疗组患者肛管收缩压及肛管排便压明显高于对照组(P<0.05)。结论:MLIFT能有效治疗ISAF、TSAF,在不损伤患者肛门括约肌情况下,对改善患者术后症状及并发症方面具有一定优势。
关键词:  改良经括约肌间瘘管结扎术  括约肌间型肛瘘  经括约肌型肛瘘  肛管测压
DOI:10.3969/j.issn.1007-6948.2023.02.004
基金项目:上海市卫生和计划生育委员会青年项目(2017Y40008);上海市青年科技英才扬帆计划资助(21YF1433300)
Study and risk factors analysis of modified transsphincteric anal fistula ligation for intersphincteric anal fistula and transsphincteric anal fistula
WU Chuang,XU Jin,WANG Qing-ming
Department of Anorectal, Shanghai Baoshan Hospital of Integrated Traditional Chinese and Western Medicine Shanghai201999, China
Abstract:
Objectives To observe the effect of Modified Ligation of the Inter-sphincteric Fistula Tract (MLIFT) on Inter-sphincteric Anal Fistula (ISAF) and Trans-sphincteric Anal Fistula TSAF. Methods A total of 190 ISAF and TSAF patients were randomly divided into treatment group (MLIFT) and control group (fistulectomy). The Visual Analogue Scale (VAS), wound bleeding, distension, urinary retention and Fecal Incontinence Severity Index (FISI) were compared between the two groups on the 1st, 3rd, 7th, 14th, 21st and 30th days after operation. The cure rate and recurrence rate of the two groups were compared. Results The cure rates of the treatment group and the control group were 87.37% and 94.75% respectively, without statistical difference (P>0.05). The recurrence rates of the treatment group and the control group were 7.37% and 2.11%, respectively, with no statistical difference (P>0.05). However, The VAS score on the 1st, 3rd, 7th, 14th day after operation and wound bleeding score on the 1st, 3rd, 7th day after surgery in the treatment group were significantly lower than the control group(P<0.01). On the 1st and 7th postoperative day of the anal distension discomfort and the 1st day after surgery urinary retention in the treatment group were significantly less than the control group (P<0.05). On the 14th day after operation, the discomfort of anal distension in the treatment group was significantly less than that in the control group (P<0.05). The anal maximal contraction pressure and anal squeez pressure of the treatment group were significantly higher than the control group at one year after operation(P<0.05). Conclusion MLIFT can effectively treatment of ISAF and TSAF, and has certain advantages in improving postoperative symptoms and complications without damaging anal sphincter.
Key words:  Modified transsphincteric anal fistula ligation  intersphincteric anal fistula  transsphincteric anal fistula  anal pressure

用微信扫一扫

用微信扫一扫